The Leland Stanford Junior University (Stanford University) has been awarded a $207,900 Project Grant from the National Institute of Biomedical Imaging and Bioengineering under the Discovery and Applied Research for Technological Innovations to Improve Human Health (CFDA 93.286) program. The grant, effective April 1, 2025 through March 31, 2028, will fund research to develop a three-cell (T cells, natural killer cells, and macrophages) synthetic immunotherapy system engineered to express chimeric antigen receptors (CARs) and synthetic cytokine receptors (SCRs). The goal is to create a synergistic, multi-cell immunotherapy that can overcome limitations of individual CAR immune cell types and improve cancer treatment. The research will involve screening libraries of CAR-SCR pairs, developing dynamic models to quantify the behavior of the three-cell system, and optimizing receptors to enhance anti-tumor activity. This work aims to provide a framework for engineering synthetic immune systems with tunable therapeutic functions for treating cancer and autoimmune diseases.
Generated 3/18/25, 2:55 AM